Measured activities for 125I-BC8-FP in target organs at 96 hours in animals treated with and without 16-mer synthetic clearing agent at 24 hours
| . | CA . | SD . | Control . | SD . |
|---|---|---|---|---|
| LN | 0.173% | ± 0.005% | 0.181% | ± 0.031% |
| Spleen | 0.287% | ± 0.008% | 0.282% | ± 0.008% |
| BM | 0.127% | ± 0.003% | 0.124% | ± 0.012% |
| . | CA . | SD . | Control . | SD . |
|---|---|---|---|---|
| LN | 0.173% | ± 0.005% | 0.181% | ± 0.031% |
| Spleen | 0.287% | ± 0.008% | 0.282% | ± 0.008% |
| BM | 0.127% | ± 0.003% | 0.124% | ± 0.012% |
A total of 45 mg/m2 of a synthetic 16-mer CA was administered intravenously 24 hours after 125I-BC8-FP (16.9 nmol/kg) and 2 hours before 111In-DOTA-biotin (1.2 mg/m2) to evaluate its impact on blood clearance and organ biodistribution. A control animal received 125I-BC8-FP and 111In-DOTA-biotin at identical time points, but no CA. The contents of the trace-labeled reagents in tissue specimens were measured in a dual-channel gamma counter and are expressed as the percentage injected dose per gram of tissue (%ID/g). SDs reflect 3 biopsy specimens from each tissue.